Shots:
- Intas Pharmaceuticals, through its US specialty division Accord BioPharma, has entered into an agreement to acquire Coherus’ Udenyca business (pegfilgrastim-cbqv), a biosimilar of Amgen’s Neulasta, to enhance Accord’s biosimilar product portfolio. Deal is expected to conclude in Q1’25
- Udenyca is indicated to reduce infection risk from febrile neutropenia in patients with non-myeloid malignancies, on myelosuppressive anti-cancer drugs and to increase survival in those exposed to myelosuppressive radiation
- Udenyca is a leukocyte growth factor available as prefilled syringe (PFS), autoinjector (AI) & on-body injector (OBI), ensuring patient’s choice & convenience
Ref: Intas Pharmaceuticals & Coherus BioSciences | Image: Intas Pharmaceuticals & Coherus BioSciences | Press Release
Related News:- Biocon Biologics Reports the US FDA’s Approval of Yesintek (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
